Marc Schwartz
Overview
Explore the profile of Marc Schwartz including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
105
Citations
1922
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Santos J, Abbott D, Bosma G, Kent A, Schwartz M, McMahon C, et al.
Leuk Lymphoma
. 2025 Mar;
:1-3.
PMID: 40080662
No abstract available.
2.
Franco I, Schwartz M, Cline K, Glazier D, Patel A
Low Urin Tract Symptoms
. 2025 Jan;
17(1):e70004.
PMID: 39800349
Objectives: To evaluate possible predictors of elevated postvoid residual volume (PVR) following onabotulinumtoxinA administration in patients with idiopathic overactive bladder (OAB), a condition that may include urinary urgency, frequency, and...
3.
Bernstein S, Schwartz M, Ifantides K
Neurourol Urodyn
. 2024 Dec;
44(2):338-344.
PMID: 39660510
Aims: OnabotulinumtoxinA (onabotA) is an approved treatment for overactive bladder (OAB). This chart review study aims to determine treatment persistence in patients receiving onabotA (100 U) via a reduced injection-site...
4.
Roloff G, Aldoss I, Kopmar N, Lin C, Dekker S, Gupta V, et al.
J Clin Oncol
. 2024 Oct;
43(5):558-566.
PMID: 39418622
Purpose: On the basis of the results of the ZUMA-3 trial, brexucabtagene autoleucel (brexu-cel), a CD19-directed chimeric antigen receptor T-cell therapy, gained US Food and Drug Administration approval in October...
5.
Shah B, Mattison R, Abboud R, Abdelmessieh P, Aldoss I, Burke P, et al.
J Natl Compr Canc Netw
. 2024 Oct;
22(8):563-576.
PMID: 39413812
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for acute lymphoblastic leukemia (ALL) provide recommendations for management of ALL, with a focus on the classification of ALL subtypes based...
6.
Gil K, Abbott D, Amaya M, Schwartz M, Gutman J, Kent A, et al.
Leuk Lymphoma
. 2024 Sep;
65(14):2228-2230.
PMID: 39229898
No abstract available.
7.
Kent A, Gil K, Jones M, Linden B, Purev E, Haverkos B, et al.
Transplant Cell Ther
. 2024 Aug;
PMID: 39154914
Despite the concurrent use of haploidentical cord (HCT) and dual cord (DCT) stem cell transplant approaches for over a decade, there have been few comparisons of their outcomes. Our objective...
8.
Aldoss I, Roloff G, Faramand R, Kopmar N, Lin C, Advani A, et al.
Blood Adv
. 2024 Aug;
8(23):6139-6147.
PMID: 39093952
The effect of prior inotuzumab ozogamicin (InO) treatment on brexucabtagene autoleucel (brexu-cel) outcomes remains unclear in adults with acute lymphoblastic leukemia (ALL). We conducted a retrospective multicenter analysis of 189...
9.
Dashtipour K, Sadeghi M, Charles D, Mehta S, Fernandez H, Schwartz M, et al.
Toxicon
. 2024 Jul;
248:108035.
PMID: 39059560
Anterocollis (AC) and retrocollis (RC) are less common cervical dystonia (CD) subtypes that are often under-represented in CD clinical trials. Herein we describe real-world demographics, disease characteristics, and treatment response...
10.
Ertem F, Rivers C, Ghaffari A, Watson A, Tang G, Schwartz M, et al.
Inflamm Bowel Dis
. 2024 Jul;
31(2):461-466.
PMID: 38953641
Background: Almost half of patients with Crohn's disease (CD) require bowel surgeries in their lifetime. Due to the high risk of postoperative disease recurrence and high rate of previous antitumor...